Good afternoon, everybody. My name is Hannu Martola, and I'm the president and CEO of Detection Technology. Welcome to Detection Technology's second quarter results webcast. I'm here to announce our results through this webcast. But before starting, just briefly, what does Detection Technology do? We are the eyes of X-ray equipment. We provide our detectors to major medical, security, and industrial OEMs. You can find our products in hospitals in computed tomography equipment, at airports for security screening, and in various industrial applications, such as battery manufacturing or food scanning for manufacturing lines, and so on. I'm pleased to now report what we have achieved after the second quarter and during the second quarter. We reached the sales of €26.1 million, growing about 4%, up from 3.5% last year. In the second quarter, we reached much better profitability, at €3.3 million, which is 12.7% of our second-quarter sales. We had quite a big variation in our business units. Our industrial business unit grew really nicely by 43%. The majority of that growth is coming from a new acquisition. We acquired Hubble and their flat panels, but also, our industrial business unit grew nicely without them. There's now, like food, industrial and so on. The various industrial markets have returned to small growth in this business. However, medical sales were a disappointment, but as expected, the healthcare sector has not been very strong. Especially in China, the healthcare reform, which has been affecting the medical sales there, was still limiting the sales. However, we have now started to see some very small positive market signals, and we expect that medical will start to slowly recover. Security sales were nice at 27%. As a big business unit, it contributes significantly to our 3.5% growth. Sales were growing in all areas, especially aviation, for security screening applications. We improved quite consistently, our year-over-year result; cash flow was really strong. And what I think is very nice, is that this is the fifth consecutive quarter that the earnings have improved for Detection Technology. On net sales by quarter, slightly better than last year. We guided flat, so this is a flat plus. So, 3.5% is still above the zero level. And actually, we have to go back to 2019 since we have had this level of sales for the second. For the second quarter on EBIT, a clear step from a year-on-year numbers. Actually, in the company, we are quite pleased with this result. I think it was as expected but slightly better than expected. But we also have to note that this 12.7 is still below the midterm target that we have set, which is 15%. But for the second quarter, the sales and results were quite acceptable. By business unit: Security has now become the largest business unit of Detection Technology, representing about 44% of our total sales, followed by medical, which after a decline, accounts for 36%. And industrial now constitutes one fifth or 20% of our sales.
On markets, we clearly grew in Europe, the Middle East, and Africa, largely driven by demand in security. So, there was a 56% year-on-year growth. Conversely, the Americas experienced a significant decline. There were some exceptional items that affected the Americas' sales. In the Asia Pacific, the sales were very much the same as last year, comprising 6% of the total, a bit down from the previous year. Europe, the Middle East, Africa accounted for about 30% and the Americas for 6% of the total sales.
Looking at the full year, the first half was roughly just shy of €50 million, or about flat compared to last year, with a 2% growth. We are looking forward to higher growth in the second half of the year, as we have expected and informed the markets. The EBITA is 11.4, which I think is a good start for the year. For the second half, we anticipate and should observe better performance. By business units:
This trend is very similar to that of the first quarter. The medical sector was heavily down due to the China healthcare reform and anti-corruption campaigns. Both the IBU and SBU saw nice growth of over 20%. By region, the Americas were down by 60%. However, Europe was up close to 40% and Asia Pacific was effectively flat, increasing by 3.2%.
Regarding finances and key figures: Just a couple of items to note here. The R&D spending was about the same as last year at €3 million, constituting 11.7% of the budget. We had very nice cash flow. That amounted to €3.9 million and €6.8 million for the first half. Investments decreased after we finalized the clean room and other facilities.
First half investments totaled €1.5 million, and out of that, the second quarter accounted for €350,000. Earnings per share stood at €0.15. Concerning strategy highlights: We have now finalized and established a subsidiary, a legal entity in India. We are building a service, manufacturing, and assembly site and center in India. We also finalized the old site and factory, ensuring we are now ready to make about 10% of our sales from that side during the second half. Furthermore, we continued launching a wide range of TFT panels from Harbor Imaging. That has gone as planned, including the new dynamic panels called IGZO panels. Many of the other events we have implemented include the target setting and KPI system within the company called OnePlus SCR, which is very similar to the known OKR system. Additionally, we are starting to use the sustainability reporting system called CSRD, which is due next year.
Regarding sales expectations, for the industrial sector, we expect double-digit growth in the third quarter, medical to turn to slight growth after a somewhat disappointing first half, and security to also continue with double-digit growth. As a company, our full guidance is that we expect our total net sales to grow in double digits for the third quarter and also for the entire second half. Our financial targets remain the same, with at least a 10% annual growth and at least a 15% or better operating margin, EBITDA. Additionally, out of the net proceeds, dividends of 30% to 60% will be distributed.
Despite some global challenges, our business outlook for the second half is quite positive, and we now expect the business to enter into double-digit growth. Although the healthcare sector in China, which is our main market, does not yet show clear signs of recovery, there are some initial signs of increasing orders and sales forecasts. The security and industrial areas, as previously mentioned, should continue to grow. This is, in a nutshell, what's currently happening. What did we accomplish in the second quarter?
If there are any questions, I would be pleased to answer them.